HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Nu Skin guidance

This article was originally published in The Rose Sheet

Executive Summary

Third quarter revenue expected to increase 13% to $282 mil., with earnings per share likely to grow about 50% to $.27-$.28, or 20% excluding the impact of a $.04 per share one-time charge in the quarter, firm says during Oct. 4 analyst call. While U.S. sales are expected to grow about 25% year-over-year driven by Pharmanex division, direct-seller's results in Japan and China will be "softer than expected," President and CEO Truman Hunt says. Japanese sales are expected to fall 8% versus the year-ago period, while China's sales volume will be down about 4% compared to the previous quarter, with sales in the region expected to be $26 mil.-$27 mil. Chinese business is struggling in anticipation of new direct sales regulations, which may not be implemented until the second or third quarter of 2005, Hunt says...

You may also be interested in...



Keeping Track: Quick Trips From Breakthrough Designation To Market

Phase III data earns a breakthrough therapy designation for Resverlogix’ apabetalone; previous companies to follow that strategy swiftly advance to NDA submission, as seen with Novartis’ capmatinib and Seattle Genetics’ tucatinib.

Breakthrough Therapy Designations: Phase II Data Is Sweet Spot For US FDA Award

Pink Sheet analysis finds that evidence from early-stage trials supports most BTD requests, but about three in 10 designations are granted on the basis of pivotal-stage data.

Medicare-For-Hmmm: A Year Of House Hearings Show Democratic Disunity

Four House hearings show how far away even many Democrats are from supporting a single payer system in the US.

UsernamePublicRestriction

Register

RS012516

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel